November 11-18, 2017
40 participants, 22 women, 18 men from 9 countries
Faculty:
D. Andes, University of Wisconsin, USA; C. Arias, University of Texas, USA; D. Bikard, Institut Pasteur, France; E. Brown, McMaster University, Canada; K. Bush, Indiana University, USA; V. Cattoir, Université de Rennes 1, France; G. Challis, University of Warwick, UK; J.‑P. Charrier, bioMérieux, France; L. Chesnel, MSD, USA; P. Courvalin, Institut Pasteur, France; L. Debarbieux, Institut Pasteur, France; J.‑D. Docquier, University of Siena, Italy; T. Dougherty, Harvard Medical School, USA; M. Gilmore, Harvard Medical School, USA; C. Giske, Karolinska Institutet, Sweden; C. Grillot-Courvalin, Institut Pasteur, France; R. Hancock, University of British Columbia, Canada; D. Hooper, Massachusetts General Hospital, USA; D. Hughes, Uppsala University, Sweden; D. Kohane, Harvard Medical School, USA; S. Lahiri, Macrolide Pharmaceuticals, USA; F. Lebreton, Harvard Medical School, USA; D. Lopez, University of Wuersburg, Germany; S. Lory, Harvard Medical School, USA; A. Mankin, University of Illinois, USA; M. McCarthy, Verizon, USA; H. Moser, Novartis, USA; A. Myers, Harvard University, USA; M. Page, Basel, Switzerland; K. Pos, Goethe University, Germany; S. Projan, MedImmune, USA; M. Pucci, Spero Therapeutics, USA; D. Rasko, University of Maryland, USA; G.‑M. Rossolini, University of Siena, Italy; H.‑G. Sahl, University of Bonn, Germany; J. Schrenzel, Geneva University Hospitals, Switzerland M.‑W. Tan, Genentech/Roche, USA; Y. Taur, Memorial Sloan Kettering Cancer Center, USA M. Trent, University of Georgia, USA; T. Walsh, Cardiff University, UK; G. Wright, McMaster University, Canada;
